rs370075755
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM1BP4BS2
The ENST00000228841.15(MYL2):c.436G>A(p.Val146Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000023 in 1,605,496 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V146A) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000228841.15 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYL2 | NM_000432.4 | c.436G>A | p.Val146Met | missense_variant | 7/7 | ENST00000228841.15 | NP_000423.2 | |
MYL2 | NM_001406745.1 | c.394G>A | p.Val132Met | missense_variant | 6/6 | NP_001393674.1 | ||
MYL2 | NM_001406916.1 | c.379G>A | p.Val127Met | missense_variant | 7/7 | NP_001393845.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYL2 | ENST00000228841.15 | c.436G>A | p.Val146Met | missense_variant | 7/7 | 1 | NM_000432.4 | ENSP00000228841 | P1 | |
MYL2 | ENST00000548438.1 | c.394G>A | p.Val132Met | missense_variant | 6/6 | 3 | ENSP00000447154 | |||
MYL2 | ENST00000663220.1 | c.379G>A | p.Val127Met | missense_variant | 7/7 | ENSP00000499568 |
Frequencies
GnomAD3 genomes AF: 0.0000199 AC: 3AN: 150834Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000281 AC: 7AN: 249038Hom.: 0 AF XY: 0.0000297 AC XY: 4AN XY: 134784
GnomAD4 exome AF: 0.0000234 AC: 34AN: 1454662Hom.: 0 Cov.: 31 AF XY: 0.0000235 AC XY: 17AN XY: 723638
GnomAD4 genome AF: 0.0000199 AC: 3AN: 150834Hom.: 0 Cov.: 31 AF XY: 0.0000272 AC XY: 2AN XY: 73594
ClinVar
Submissions by phenotype
Cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | May 18, 2023 | This missense variant replaces valine with methionine at codon 146 of the MYL2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). An experimental functional study in zebrafish has shown that this variant causes compromised cardiac development and structural disorders (PMID: 35993536). This variant has been reported in an individual affected with congenital heart disease, including coarctation of the aorta, ventricular septal defect, and mitral insufficiency (PMID: 35993536). This variant has been identified in 10/280354 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jun 10, 2019 | - - |
Congenital heart disease Pathogenic:1
Pathogenic, no assertion criteria provided | case-control | Hongyan Wang Laboratory, Fudan University | - | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 19, 2024 | Variant summary: MYL2 c.436G>A (p.Val146Met) results in a conservative amino acid change located in the EF-hand domain (IPR002048) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 249038 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.436G>A has been reported in the literature in individuals affected with Cardiomyopathy (Zhang_2022). These report(s) do not provide unequivocal conclusions about association of the variant with Hypertrophic Cardiomyopathy. One publication reports experimental evidence evaluating an impact on protein function in zebrafish model and has shown that this variant causes defective cardiac development (Zhang_2022). The following publication have been ascertained in the context of this evaluation (PMID: 35993536). ClinVar contains an entry for this variant (Variation ID: 520474). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Hypertrophic cardiomyopathy 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 17, 2023 | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 146 of the MYL2 protein (p.Val146Met). This variant is present in population databases (rs370075755, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with MYL2-related conditions. ClinVar contains an entry for this variant (Variation ID: 520474). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects MYL2 function (PMID: 35993536). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Primary familial hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Jul 29, 2016 | - - |
Hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Aug 13, 2024 | This missense variant replaces valine with methionine at codon 146 of the MYL2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). An experimental functional study in zebrafish has shown that this variant causes compromised cardiac development and structural disorders (PMID: 35993536). This variant has been reported in an individual affected with congenital heart disease, including coarctation of the aorta, ventricular septal defect, and mitral insufficiency (PMID: 35993536). This variant has been identified in 10/280354 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 07, 2023 | The p.V146M variant (also known as c.436G>A), located in coding exon 7 of the MYL2 gene, results from a G to A substitution at nucleotide position 436. The valine at codon 146 is replaced by methionine, an amino acid with highly similar properties. This variant has been detected in an individual with congenital heart disease, and a functional study suggested this variant may impact protein function in the context of embryonic zebrafish cardiac development; however, the physiological relevance of this finding is unclear (Zhang Y et al. Mol Genet Genomic Med. 2022 Oct;10(10):e2041). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at